Relationship between serum GAD-Ab and the genetic polymorphisms of GAD2 and type 2 diabetes mellitus

Q. Li¹, Z.R. Qiao², D.B. Liu¹, J.T. Zeng³, J. Zhang³, Y. Bo³, H.Y. Zu³, Q. Hu³, X. Wu² and S.S. Dong³

¹Department of Laboratory Medicine, People’s Hospital of Changshou, Chongqing, China
²Department of Endocrinology, People’s Hospital of Changshou, Chongqing, China
³Department of Laboratory Medicine, People’s Hospital of Changshou, Chongqing, China

Corresponding author: Q. Li
E-mail: qlzrcn@126.com

Received March 17, 2014
Accepted July 4, 2014
Published April 10, 2015
DOI http://dx.doi.org/10.4238/2015.April.10.10

ABSTRACT. In this study, we investigated the relationship between serum glutamic acid decarboxylase (GAD) autoantibody (Ab) levels and single nucleotide polymorphisms (SNPs) of the glutamic acid decarboxylase 2 (GAD2) 5'-untranslated region and the susceptibility to type 2 diabetes in the Han population. The distributions of patients with SNPs in the GAD2 5'-untranslated region (rs2236418, rs185649317, and rs8190590) and type 2 diabetes and that of the healthy group were genotyped and analyzed using Sequenom MassArray SNP genotyping. GAD-Ab levels were also detected. The frequency distributions of the AA, AG, and GG genotypes in the polymorphic site rs2236418 in the diabetes GAD-Ab-positive group were 45.9, 42.8, and 11.4%, respectively, whereas those in the control group were 36.6, 43.7, and 19.8%, respectively. The difference between the 2 groups was stas-
tically significant (P < 0.05). Unlike the GG genotype, the AA and AA + AG genotypes increased the risk of GAD-Ab (odds ratios (95% confidence intervals) = 2.623 (1.351-4.937) and 2.152 (1.375-4.202), respectively). The associations of the 3 SNPs of the GAD2 gene 5'-untranslated region polymorphisms with susceptibility to type 2 diabetes in the Chongqing Han population were significant. The SNP of rs2236418 in the Chongqing Han population of diabetic patients with serum GAD-Ab levels was significantly correlated with the SNPs rs185649317 and rs8190590.

**Key words:** Diabetes mellitus; Glutamic acid decarboxylase 2; GAD-Ab; Single nucleotide polymorphism

### INTRODUCTION

Diabetes is a lifelong disease with no cure. Type 2 diabetes mellitus (T2DM) is a typical multi-gene disease caused by several genetic factors (Scott et al., 2007; Yasuda et al., 2008; Li et al., 2013). A single factor poses little risk; the cumulative effect of several polymorphic loci increases the risk of T2DM. Hypoglycemic drugs and oral insulin are the primary means of controlling the blood sugar of T2DM patients. The illness occurs for a long duration during which islet dysfunction is severe, and secondary failure to sulfonylureas may occur. Even when the combined application of various oral hypoglycemic drugs does not effectively control blood sugar, insulin treatment must be continued for as long as possible to maintain the blood sugar at proper levels. The rational application of insulin can protect and restore cell functions. Functional lipids and coagulation and endothelial systems effectively control blood sugar and its induced disorders. The optimal administration time of insulin must be determined to effectively delay its subsequent complications and perform its important functions. Insulin release has an important function in the pathogenesis of T2DM (Genuith et al., 2003; Hansen et al., 2010). Glutamic acid decarboxylase (GAD) is the body’s normal catalytic glutamic acid protease and gamma-aminobutyric acid involved in the synthesis and secretion of insulin from pancreatic β-cells. GAD is a key factor in the immune response for initiating the target antigen, specificity the inhibition caused by autoimmune reactions (Boutin et al., 2003) and induction of immune tolerance. GAD autoantibodies (GAD-Ab) can cause dysfunction of pancreatic β-cell autoimmunity (Kadiyala et al., 2010), which can gradually lead to islet β-cell failure. In cases, showing trends towards clinical manifestations of type 1 diabetes mellitus, insulin therapy is necessary (Prokopenko et al., 2008; Ali et al., 2011).

In this study, single nucleotide polymorphisms (SNPs) in the 5'-untranslated region (UTR) of the glutamic acid decarboxylase 2 (GAD2) gene’s regulatory region were selected based on bioinformatic analysis. SNPs were selected from the dbSNP database in the 5'-UTR of GAD2 gene loci. Three SNP locus genotypes and serum GAD-Ab levels were detected in 497 patients and 500 normal controls. The optimal administration time of insulin therapy was determined based on personalized treatment data and theory by exploring the relationship between serum GAD-Ab level and GAD2 gene polymorphism (Johnson et al., 2002; Wheeler and Barroso, 2011).
MATERIAL AND METHODS

Specimens

The blood samples from the 497 patients with T2DM and 500 normal controls were collected from the Changshou District People’s Hospital from 2009 to 2011. The subjects were Han Chinese residents who lived in Chongqing and the surrounding areas, and they were mostly unrelated to one another. All cases included diagnosed clinical data. The control group recruited over the same period consisted of healthy volunteers. The case group consisted of 208 males and 289 females with an average age of 62.42 ± 14.89 years. The healthy control group consisted of 264 males and 236 females with an average age of 59.44 ± 15.22 years. After obtaining informed consent from the participants, 1-2 mL peripheral venous blood samples were collected and stored at -70°C. This study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of People’s Hospital of Chongqing. Written informed consent was obtained from all participants.

SNP loci

The 3 SNP sites rs2236418, rs185649317, and rs8190590 specified in the www.snpedia.com database were located in the 5'-UTR region of the GAD2 gene. The Chinese population data in the HapMap database revealed the occurrence of polymorphisms.

DNA extraction

DNA was manually extracted from 200 μL peripheral blood using a DNA extraction kit (Tiangen Biotechnology Co., Ltd., TIANamp Genomic DNA Kit, Beijing, China), and stored at -70°C.

Primer design and synthesis

For the gene target sequences of GAD2 and selected SNPs, the Sequenom MassArray Designer 3.0 software (San Diego, CA, USA) was used to design primers for polymerase chain reaction (PCR) amplification and extension of the 3 sites, including the specific amplification primer and extension sequences of TCTCCGCCTTTTCTGAGTCCGGGC and TGGAGCAGGTCGCGCTGCGAGTG, rs2236418 single base TAGTCCCGGTCTCTTTTAA, single base extension for rs185649317 primer sequence CACGCGCGCGCAGGGCCAAGCC CGAG, and single base extension for rs8190590 primer sequence CAAGCCCGAGGCAGC TCAGC. The primers were synthesized by Shanghai Invitrogen Corporation (Carlsbad, CA, USA).

Genotyping analysis

The SNP loci of the GAD2 gene promoter were genotyped using Sequenom MassARRAY mass spectrometry array technology.

After extracting and purifying the quantitatively diluted sample of genomic DNA, the resulting sample was placed on a 384-well plate. PCR amplification was performed using the following concentrations of reactants: 0.1 U Taq polymerase, 5 ng genomic DNA, 2.5 pmol
of each PCR primer, and 2.5 mmol dNTPs. The PCR conditions were as follows: 95°C for 15 min, 45 cycles at 95°C for 20 s, 56°C for 30 s, and 72°C for 30 s. The remaining dNTPs were removed by treatment with 0.3 U shrimp alkaline phosphatase.

The single base extension reaction was conducted by adding 5.4 pmol extension primers, 50 μmol ddNTP mixture, and 0.5 U Thermosequenase DNA polymerase. The reaction conditions were as follows: 94°C for 2 min, 40 cycles at 94°C for 5 s, 50°C for 5 s, and 72°C for 5 s. The reaction products were subjected to resin desalination for 20 min using a spotting instrument SpectroCHIP (Sequenom). After spotting, chip matrix-assisted laser desorption ionization time-of-flight mass spectrometry (SpectroREADER; Sequenom) was performed. DNA samples were evaluated for quality control and to ensure a genotyping success rate of >95%.

**Serum GAD-Ab**

The patients diagnosed with T2DM were subjected to drug therapy for 48 h, after which the therapy was stopped. In the morning of the third day, 75 glucose was used (300 mL water) for the oral glucose tolerance test. The contents of the GAD-Ab protein chip for 0 min serum samples were obtained, and specific methods were performed according to manufacturer instructions.

**Statistical analysis**

The Hardy Weinberg equilibrium test was performed for both the case and control groups. Genotype frequencies were detected using the SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA). The chi-squared test was conducted to determine the differences in the allelic and genotype frequency distributions. GAD-Ab test results were used to classify subjects into GAD-Ab-positive and GAD-Ab-negative groups. The differences in the genotype frequency distribution of the SNP locus for chi-square analysis were determined. Non-conditional logistic regression was used to calculate the P values of different genotypes. The significance level was set at 0.05.

**RESULTS**

The case group matched the control group for age; differences were not statistically significant (P > 0.05). The frequency distributions of the 3 genotypes were in accordance with Hardy-Weinberg equilibrium in both groups (P > 0.05).

**SNP site rs2236418**

The AA, AG, and GG genotypes in rs2236418 were detected in the Chongqing Han population. The frequency distributions for AA, AG, and GG in the case group were 40.8, 43.2, and 15.9%, respectively. The frequency distributions for AA, AG, and GG in the healthy control group were 37.4, 45.8, and 16.8%, respectively. The differences were not significant ($\chi^2 = 0.312$ and $P = 0.862$; Table 1).
Table 1. Relationship between rs2236418 genotype distribution and susceptibility to diabetes [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs2236418</th>
<th>Case group</th>
<th>Control group</th>
<th>( \chi^2 )</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>203 (40.8)</td>
<td>187 (37.4)</td>
<td>0.312</td>
<td>0.862</td>
</tr>
<tr>
<td>AG</td>
<td>215 (43.2)</td>
<td>229 (45.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>79 (15.9)</td>
<td>84 (16.8)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For the GAD-Ab level of the case group, 229 cases showed positive results and 268 cases showed negative results. The frequency distributions of AA, AG, and GG in the GAD-Ab-positive group were 45.9, 42.8, and 11.4%, respectively. The frequency distributions of AA, AG, and GG in the GAD-Ab-negative group were 36.6, 43.7, and 19.8%, respectively. The differences were statistically significant (\( \chi^2 = 8.085 \) and \( P = 0.013 \); Table 2).

Table 2. Relationship between rs2236418 genotype distribution and serum levels of GAD-Ab [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs2236418</th>
<th>GAD-Ab-positive</th>
<th>GAD-Ab-negative</th>
<th>( \chi^2 )</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>105 (45.9)</td>
<td>98 (36.6)</td>
<td>8.085</td>
<td>0.013</td>
</tr>
<tr>
<td>AG</td>
<td>98 (42.8)</td>
<td>117 (43.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>26 (11.4)</td>
<td>53 (19.8)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Logistic regression analysis, adjusted for gender and age, was performed to evaluate the level of correlation between rs2236418 and T2DM patients with GAD-Ab. Unlike the GG genotype, the AA and AA + AG genotypes increased the risk of GAD-Ab. The respective odds ratios (ORs) [95% confidence interval (CI)] were 2.623 (1.351-4.937) and 2.152 (1.375-4.202) (Table 3).

Table 3. Risk of diabetes related to rs2236418 genotype and GAD-Ab.

<table>
<thead>
<tr>
<th>Genotype of rs2236418</th>
<th>GAD-Ab-positive</th>
<th>GAD-Ab-negative</th>
<th>P</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GG</td>
<td>26</td>
<td>53</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>AA</td>
<td>105</td>
<td>98</td>
<td>0.005</td>
<td>2.623 (1.351-4.937)</td>
</tr>
<tr>
<td>AG</td>
<td>98</td>
<td>117</td>
<td>0.063</td>
<td>1.822 (0.892-3.463)</td>
</tr>
<tr>
<td>AA+AG</td>
<td>203</td>
<td>215</td>
<td>0.021</td>
<td>2.152 (1.375-4.202)</td>
</tr>
</tbody>
</table>

SNP site rs185649317

The AA, AG, and GG genotypes in rs185649317 in the Chongqing Han population were determined. The frequency distributions of AA, AG, and GG in the T2-DM group were 6.6, 39.4, and 53.9%, respectively. The frequency distributions of AA, AG, and GG in the healthy control group were 6.0, 40.6, and 53.4%. The differences were not statistically significant (\( \chi^2 = 0.651 \) and \( P = 0.967 \); Table 4).

Table 4. Relationship between rs185649317 genotype distribution and susceptibility to diabetes [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs185649317</th>
<th>Case group</th>
<th>Control group</th>
<th>( \chi^2 )</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>33 (6.6)</td>
<td>30 (6.0)</td>
<td>0.651</td>
<td>0.967</td>
</tr>
<tr>
<td>AG</td>
<td>196 (39.4)</td>
<td>203 (40.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>268 (53.9)</td>
<td>267 (53.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The frequency distributions of AA, AG, and GG in the GAD-Ab-positive group were 7.0, 41.9, and 51.1%, respectively. The frequency distributions of AA, AG, and GG in the GAD-Ab-negative group were 6.3, 37.3, and 56.3%, respectively. The differences were not statistically significant ($\chi^2 = 0.621$ and $P = 0.713$; Table 5).

Table 5. Relationship between rs185649317 genotype distribution and serum levels of GAD-Ab [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs185649317</th>
<th>GAD-Ab-positive</th>
<th>GAD-Ab-negative</th>
<th>$\chi^2$</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>16 (7.0)</td>
<td>17 (6.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AG</td>
<td>96 (41.9)</td>
<td>100 (37.3)</td>
<td>0.621</td>
<td>0.713</td>
</tr>
<tr>
<td>GG</td>
<td>117 (51.1)</td>
<td>151 (56.3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SNP site rs8190590

The CC, CT, and TT genotypes in rs8190590 of the Chongqing Han population were determined. The frequency distributions of CC, CT, and TT in the T2-DM group were 52.1, 36.4, and 11.5%, respectively. The frequency distributions of CC, CT, and TT in the control group were 44.4, 39.4, and 16.2%, respectively. The differences were not statistically significant ($\chi^2 = 0.197$ and $P = 0.232$; Table 6).

Table 6. Relationship between rs8190590 genotype distribution and susceptibility to diabetes [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs8190590</th>
<th>Case group</th>
<th>Control group</th>
<th>$\chi^2$</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC</td>
<td>259 (52.1)</td>
<td>222 (44.4)</td>
<td>0.197</td>
<td>0.232</td>
</tr>
<tr>
<td>CT</td>
<td>181 (36.4)</td>
<td>197 (39.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>57 (11.5)</td>
<td>81 (16.2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The frequency distributions of CC, CT, and TT in the GAD-Ab-positive group were 55.5, 26.6, and 17.9%, respectively. The frequency distributions of CC, CT, and TT in the GAD-Ab-negative group were 49.3, 44.8 and 6.0%, respectively. The differences were not statistically significant ($\chi^2 = 0.546$ and $P = 0.641$; Table 7).

Table 7. Relationship between rs8190590 genotype distribution and serum levels of GAD-Ab [N (%)].

<table>
<thead>
<tr>
<th>Genotype of rs8190590</th>
<th>GAD-Ab-positive</th>
<th>GAD-Ab-negative</th>
<th>$\chi^2$</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>127 (55.5)</td>
<td>132 (49.3)</td>
<td>0.546</td>
<td>0.641</td>
</tr>
<tr>
<td>AG</td>
<td>61 (26.6)</td>
<td>120 (44.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>41 (17.9)</td>
<td>16 (6.0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

$GAD2$ encodes GAD65, which is considered to be one of the most important islet autoantigens. $GAD2$ contains 1758 nucleotides, which encode for 585-amino acid residues (Kaufman et al., 1993). Small-scale clinical tests showed that $GAD2$ may delay latent autoimmune diabetes in adults with no significant side effects. GAD is primarily expressed in the brain and islet B cell-secretory granules. It occurs in 2 isoforms, GAD2 and GAD1, and is located on chromosomes 10 and 2; their non-allelic molecular weights are approximately 65.
and 67 kDa, and thus are often referred to as GAD65 and GAD67 (Boutin et al., 2003; Jayakrishnan et al., 2011). GAD65 and GAD67 share 65% amino acid sequence identity. Their main difference lies in their amino termini in amino acids 325-355. In different types of animals, GAD is expressed in the islets. The human islet only contains GAD2 (Karlsen et al., 1991; Jun et al., 2002).

GAD has two isozymes, but mainly for GAD-Ab GAD2 (Jayakrishnan et al., 2011; Sosenko et al., 2011). After the onset of diabetes, GAD-Ab appears earlier than other autoantibodies and is present for a longer duration; the age span, positive rate, and other characteristics of GAD-Ab can be detected through the diagnosis of latent autoimmune diabetes in adults (Appel et al., 2009). Recent studies found that T2DM patients were positive for GAD-Ab; the viability of islet T-cell responses during positive immunity has also been examined (Brooks-Worrell et al., 2011).

In a case-control study involving 575 obese patients and 646 healthy subjects, Boutin et al. (2003) found that gene polymorphisms in GAD2 sites of the 61450 C>A and 83897 T>A haplotypes had a protective effect on obesity (OR = 0.81, 95%CI = 0.681-0.972, P = 0.0049), and confirmed the SNP -243 A>G obesity susceptibility locus (OR = 1.3, 95%CI = 1.053-1.585, P = 0.014). The 3 SNPs were significantly associated with GAD-Ab levels (P = 0.003, 0.047, and 0.006) (Davies et al., 2008). However, in a study examining the GAD2 gene polymorphism in type 1 DM, Johnson et al. (2002) selected SNP loci covering the GAD2 gene exon 3'-UTR, 5'-UTR, and 5'-upstream region, but failed to detect the GAD2 gene polymorphism in patients with type 1 DM in 2 selected European populations (Boutin et al., 2003; Hampe et al., 2007).

A case-control study was conducted that included 497 patients with T2DM and 500 normal controls. Patients were genotyped, and the SNP locus for the 3 genotypes of the GAD2 5'-UTR area was selected. However, no significant correlation between the GAD2 gene and susceptibility to T2DM was found in the Chongqing Han population. Further evaluation indicated that SNP rs2236418 was significantly associated with the Chongqing Han population of diabetic patients and serum GAD-Ab levels. For the A allele genotype, the AA and AA + AG genotypes were correlated with a significant increase in GAD-Ab-positive results.

This study was limited to the Chongqing population; SNPs often show ethnic and regional differences. Thus, the association of GAD2 5'-UTR polymorphic loci with susceptibility to T2DM and the relationship of rs2236418 with T2DM in patients with GAD-Ab should be examined in a larger population and including other ethnic groups. Gene polymorphisms and T2DM-related mechanisms must also be further examined.

Conflicts of interest

The authors declare no conflict of interest.

REFERENCES


